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CDKN2A: The IVS2-105A/G Intronic Mutation Found in an
Italian Patient Affected by Eight Primary Melanomas
To the Editor:
The CDKN2A gene, located in 9p21, encodes two distinct
tumor suppressor proteins: p16/INK4A and p14/ARF. Exons
1a, 2, and 3 give rise to protein p16/INK4A, which is part of
the cyclin D1/CDK4/p16/pRB signaling pathway and plays
the role of proliferation inhibitor of normal cells (Dracopoli
and Fountain, 1996). In contrast, exon 1b, spliced to exons
2 and 3, in a different reading frame, encodes p14/ARF,
which acts through the MDM2/p53 pathway (Pomerantz
et al, 1998; Stott et al, 1998).
CDKN2A is frequently mutated or deleted in a wide
variety of tumors (Nobori et al, 1994; Kamb et al, 1994;
Pollock et al, 1996), whereas its germline mutations are the
most common cause of inherited susceptibility to melano-
ma having been described worldwide in melanoma families
and in individuals with multiple primary melanomas (Ruas
and Peters, 1998; Greene, 1999; Hashemi et al, 2000).
Although it is possible to identify a CDKN2A variation
associated with melanoma susceptibility in about 25% of
melanoma-prone families, a significant number of kindreds
linked to 9p21 do not carry alterations in the CDKN2A-
coding region (Liu et al, 1997; Newton Bishop et al, 1999).
This phenomenon may be attributable to possible additional
genes located in 9p21 involved in melanoma predisposition
or to the presence of nondetected CDKN2A mutations. Muta-
tional analyses performed worldwide in many melanoma-
prone families has mainly focused on the CDKN2A-coding
region and intron/exon boundaries. The first evidence of
clinically relevant germline noncoding CDKN2A mutations
come from the identification in Canadian subjects of a
variant located 34 bases upstream the CDKN2A exon 1a
initiation codon (Liu et al, 1999). Subsequently, Harland et al
(2001) described in six English melanoma-prone families a
deep CDKN2A intron 2 mutation (A to G), introducing a
functional false GT splice donor site, at 105 nucleotides
from exon 3. These authors were able to demonstrate that
the IVS2-105A/G mutation partially abolishes the function of
the wild-type CDKN2A intron 2 splice donor site, resulting in
the production of three different transcripts: the wild-type
one, plus two aberrantly spliced mRNAs. The predicted
protein derived from the two aberrant mature transcripts
diverges from the wild-type p16 only in the last four amino
acids, with no apparent effect on protein function. Harland
et al (2001) proposed that the CDKN2A intronic mutation
could act by causing a low level export of mature mRNA
from the nucleus to the cytoplasm. In addition, all carriers of
the IVS2-105 variant had the same haplotype for 9p21
markers, indicating the common origin of the mutation in the
English population.
To determine whether the IVS2-105 variant may play a
role in our Italian melanoma families and multiple melanoma
cases that do not harbor CDKN2A-coding mutations, we
analyzed intron 2 and identified the variant in a man aged 49
y affected by sporadic multiple melanoma. The patient with
blue eyes, cutaneus phototype 2, multiple freckles and
more than 50 acquired cutaneous melanocytic nevi devel-
oped 8 primary cutaneous melanomas, five of which
removed at age 37.
Investigation of the patient’s relatives (Fig 1) showed that
although no other family members are affected by melano-
ma, the patients maternal first cousin (son of patients
mother’s monozygotic twin) died at age 28 from diffuse lung
metastasis, histologically defined as mucinous carcinoma.
The primary tumor was never identified.
Sequencing analysis of CDKN2A exons 1a, 1b, and 2;
coding region of exon 3; partial 30UTR; and terminal
fragment of intron 2 showed that our patient was hetero-
zygous for the IVS2-105A/G mutation (Fig 2). The detection
of this variant, never described before except in English
melanoma-prone families, led us to check also the
unaffected parents to verify the possible transmission. We
did not detect the CDKN2A variant in either parent. To
define if the deep intronic variant was a new mutation
arising on a different haplotype from the English families
and, at the same time, to rule out false paternity, we
haplotyped CDKN2A surrounding markers in the patient
and his parents. The analysis of the same 9p21 micro-
satellite markers utilized by Harland et al (2001) demon-
strated that the patient inherited from his parents two
haplotypes that profoundly differ from the common one
present in the English melanoma-prone families. CDKN2A
analysis extended to our patient’s two children detected the
IVS2-105A/G variant in the 20-y-old unaffected son.
Our findings suggest that the IVS2-105 base could
represent a mutational hot spot and that the IVS2–105A/G
is a recurrent mutation, having arisen independently at least
twice. In addition, our results confirm that the IVS2-105
variant may be a causative mutation for melanoma devel-
opment, making it its linkage disequilibrium with a possible
‘‘real’’ mutation, in English melanoma-prone families, unlikely.
MC1R gene analysis of the proband and the family
revealed that our patient is a compound heterozygote for
the Val60Leu and the Arg160Trp common variant alleles that
could represent a further genetic factor predisposing to
melanoma (Box et al, 2001; van der Velden et al, 2001). The
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patient’s daughter is homozygous for the Arg160Trp MC1R
variant, while the son, who inherited the CDKN2A IVS2-105
and MC1R Arg160Trp variants from his father, is presumably
at significant risk of melanoma development.
Furthermore, the premature death in the patient’s first
cousin at the age of 28 in consequence of diffuse lung
cancer metastases may indicate that another cancer gene
may be segregating through the kindred, cooperating with
the IVS2-105 and with the MC1R variants in development of
melanoma in our proband.
In conclusion, our study seems to confirm the role of the
IVS2-105A/G mutation in melanoma susceptibility. It is thus
critical take into account the possibility of this intronic
CDKN2A variant in patients with no coding sequence
mutations, to improve the accuracy of genetic counseling.
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Figure 1
Patient’s family pedigree. The patient
(proband) is individual III:2. His cousin
(III:5) died at age 28 from lung metastasis
of unknown origin. Genotypes are shown
below various individuals, with CDKN2A
genotype above and MC1R below.
Figure 2
Chromatogram showing the IVS2-105A/G CDKN2A variant. The
heterozygous A/G peak is easily detected.
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